PHENOBARBITAL WITH BELLADONNA ALKALOIDS - MINT- phenobarbital, hyoscyamine sulfate, atropine sulfate, scopolamine hydrobromide e

País: Estados Unidos

Idioma: inglés

Fuente: NLM (National Library of Medicine)

Ingredientes activos:

PHENOBARBITAL (UNII: YQE403BP4D) (PHENOBARBITAL - UNII:YQE403BP4D), HYOSCYAMINE SULFATE (UNII: F2R8V82B84) (HYOSCYAMINE - UNII:PX44XO846X), ATROPINE SULFATE (UNII: 03J5ZE7KA5) (ATROPINE - UNII:7C0697DR9I), SCOPOLAMINE HYDROBROMIDE (UNII: 451IFR0GXB) (SCOPOLAMINE - UNII:DL48G20X8X)

Disponible desde:

Bryant Ranch Prepack

Vía de administración:

ORAL

tipo de receta:

PRESCRIPTION DRUG

indicaciones terapéuticas:

Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the indications as follows: "Possibly" effective: For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. May also be useful as adjunctive therapy in the treatment of duodenal ulcer. Final classification of the less-than-effective indications requires further investigation. IT HAS NOT BEEN SHOWN CONCLUSIVELY WHETHER ANTICHOLINERGIC/ANTISPASMODIC DRUGS AID IN THE HEALING OF A DUODENAL ULCER, DECREASE THE RATE OF RECURRENCES OR PREVENT COMPLICATIONS. - glaucoma; - obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); - obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); - paralytic ileus, intestinal atony of the elderly or debilitated patient; - unstable cardiovascular status in acute hemorrhage; - se

Resumen del producto:

Phenobarbital with Belladonna Alkaloids Elixir is a green colored, mint flavored liquid. 16 fl oz (473 mL) bottles - NDC 63629-2052-1 Avoid Freezing Store Phenobarbital with Belladonna Alkaloids Elixir at 20°- 25°C (68° - 77°F) [see USP Controlled Room Temperature]. Protect from light and moisture. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. DEA EXEMPT PRODUCT

Estado de Autorización:

unapproved drug other

Ficha técnica

PHENOBARBITAL WITH BELLADONNA ALKALOIDS - MINT- PHENOBARBITAL,
HYOSCYAMINE SULFATE, ATROPINE SULFATE, SCOPOLAMINE HYDROBROMIDE ELIXIR
BRYANT RANCH PREPACK
_Disclaimer: This drug has not been found by FDA to be safe and
effective, and this_
_labeling has not been approved by FDA. For further information about
unapproved_
_drugs, click here._
----------
PHENOBARBITAL WITH BELLADONNA ALKALOIDS ELIXIR - MINT
RX ONLY
DESCRIPTION
PHENOBARBITAL WITH BELLADONNA ALKALOIDS ELIXIR - MINT
Each 5 mL (teaspoonful) of elixir (alcohol not more than 23.8%)
contains:
Phenobarbital, USP.............................. 16.2 mg
Hyoscyamine Sulfate, USP............... 0.1037 mg
Atropine Sulfate, USP...................... 0.0194 mg
Scopolamine Hydrobromide, USP.... 0.0065 mg
INACTIVE INGREDIENTS
Glycerin, Ethyl Alcohol, Sorbitol, Sucrose, Saccharin Sodium, FD&C
Blue No. 1, FD&C
Yellow No. 5, Peppermint Flavor, and Water.
CLINICAL PHARMACOLOGY
This drug combination provides natural belladonna alkaloids in a
specific, fixed ratio
combined with phenobarbital to provide peripheral
anticholinergic/antispasmodic action
and mild sedation.
INDICATIONS AND USAGE
Based on a review of this drug by the National Academy of
Sciences-National Research
Council and/or other information, FDA has classified the indications
as follows: "Possibly"
effective: For use as adjunctive therapy in the treatment of irritable
bowel syndrome
(irritable colon, spastic colon, mucous colitis) and acute
enterocolitis.
May also be useful as adjunctive therapy in the treatment of duodenal
ulcer.
Final classification of the less-than-effective indications requires
further investigation.
IT HAS NOT BEEN SHOWN CONCLUSIVELY WHETHER
ANTICHOLINERGIC/ANTISPASMODIC DRUGS AID IN THE HEALING OF A DUODENAL
ULCER, DECREASE THE RATE OF RECURRENCES OR PREVENT COMPLICATIONS.
CONTRAINDICATIONS
glaucoma;
obstructive uropathy (for example, bladder neck obstruction due to
prostatic
hypertrophy);
obstructive disease of the gastrointestinal tract (as in achalasia,
pyloroduodenal
stenosis, etc.)